Fepixnebart
Based on 3 publication(s) in Google Scholar
Fepixnebart (LY3016859) is a humanized monoclonal hIgG4 antibody, which binds and neutralizes only TGFα and epiregulin with high affinity. Fepixnebart can be used for the study of diabetic nephropathy and broad-spectrum chronic pain, including diabetic peripheral neuropathic pain (DPNP), signs and symptoms of osteoarthritis (OA), and chronic low back pain (CLBP).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 96.46%
- CAS 番号: 2489584-93-0
- 分子量:145.44 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
MedChemExpress(MCE)の使用を引用している文献 Fepixnebart
MoreEGFR アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
Isotype
Human IgG4 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
TGFA
臨床実験
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
遺伝子ID
アクセッション番号
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG4 kappa
アプリケーション
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow cytometric analysis of 1.5X106 Balb/3T3 cells with Fepixnebart (HY-P990071, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 (S228P) kappa, Isotype Control (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
化学情報
-
CAS 番号 2489584-93-0
-
性状 Liquid
-
分子量 145.44 kDa
-
Color Colorless to light yellow
-
SMILES
[Fepixnebart]
-
別名
LY-3016859
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
NPJ Breast Cancer
TGF-α/EGFR-mediated lymphatic metastasis reveals a repositionable therapeutic target in breast cancer. [Abstract]2026 Apr 3;12(1):52. PMID: 41932901 -
-
純度とドキュメンテーション
-
データシート (258 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
[1]. Boyles JS, et al. Structural basis of selectivity and neutralizing activity of a TGFα/epiregulin specific antibody. Protein Sci. 2016 Nov;25(11):2028-2036. [Content Brief]
[2]. James DE, et al. Population Pharmacokinetics and Pharmacodynamics of Fepixnebart (LY3016859) and Epiregulin in Patients with Chronic Pain. Clin Pharmacokinet. 2025 May;64(5):757-767. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)